1 A gene-based clustering approach reveals QSOX1/IL1RAP as promising

2 biomarkers for the severity of non-alcoholic fatty liver disease

- 3
- 4 Wenfeng Ma^{1,2,3,4}, Jinrong Huang², Benqiang Cai^{1,4}, Mumin Shao^{6,7}, Xuewen Yu^{6,7},
- 5 Mikkel Breinholt Kjær^{5,8}, Minling Lv^{1,4}, Xin Zhong^{1,4}, Shaomin Xu^{1,4}, Bolin Zhan^{1,4},
- 6 Qun Li^{1,4}, Qi Huang^{1,4}, Mengqing Ma^{1,4}, Lei Cheng², Yonglun Luo^{2,3}*, Henning
- 7 Grønbæk ⁵*, Xiaozhou Zhou ^{1,4}*, Lin Lin ^{2,3}*
- 8
- 9 1 Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital,
- 10 Shenzhen, Guangdong 518033, China.
- 11 2 Department of Biomedicine, Aarhus University, Aarhus, Denmark.
- 12 3 Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
- 13 4 Department of Liver Disease, The Fourth Clinical Medical College of Guangzhou
- 14 University of Chinese Medicine, Shenzhen, 518033, China.
- 15 5 Department of Hepatology and Gastroenterology, Aarhus University Hospital,
- 16 Aarhus, Denmark.
- 17 6 Department of Pathology, Shenzhen Traditional Chinese Medicine Hospital,
- 18 Shenzhen, Guangdong 518033, China.
- 19 7 Department of Pathology, The Fourth Clinical Medical College of Guangzhou
- 20 University of Chinese Medicine, Shenzhen, 518033, China.
- 21 8 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- 22 * = corresponding author
- 23
- 24
- 25
- 26

27 Highlights

28

- 29 RNA-seq data from 625 liver specimens comprising healthy controls and NAFLD
- 30 patients with increasing severity were utilized for screening NAFLD biomarkers.
- 31

٠

An unsupervised method for clustering genes based on the similarity of gene expression trajectory across all samples enhanced the discovery of novel effective non-invasive NAFLD biomarkers.

35 •

- 36 QSOX1, IL1RAP, and especially the QSOX1/IL1RAP ratio, were found to be associated
- 37 with NAFLD severity.

38 •

- 39 The high sensitivity of the QSOX1/IL1RAP ratio in predicting NAFLD severity was
- 40 validated with plasma proteomics quantification (AUROC = 0.95) and ELISA (AUROC =

41 0.82) in two independent patient cohorts.

42

44 Abstract

45 Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is a progressive liver 46 disease that ranges from simple steatosis to inflammation, fibrosis, and cirrhosis. To 47 address the unmet need for new NAFLD biomarkers, we aimed to identify candidate 48 biomarkers using publicly available RNA sequencing (RNA-seq) and proteomics data. 49 Methods: An approach involving unsupervised gene clustering was performed using 50 homogeneously processed and integrated RNA-seq data of 625 liver specimens to 51 screen for NAFLD biomarkers, in combination with public proteomics data from 52 healthy controls and NAFLD patients. Additionally, we validated the results in the 53 NAFLD and healthy cohorts using enzyme-linked immunosorbent assay (ELISA) of 54 plasma and immunohistochemical staining (IHC) of liver samples.

55 **Results:** We generated a database (https://dreamapp.biomed.au.dk/NAFLD/) for 56 exploring gene expression changes along NAFLD progression to facilitate the 57 identification of genes and pathways involved in the disease's progression. Through 58 cross-analysis of the gene and protein clusters, we identified 38 genes as potential 59 biomarkers for NAFLD severity. Up-regulation of Quiescin sulfhydryl oxidase 1 60 (QSOX1) and down-regulation of Interleukin-1 receptor accessory protein (IL1RAP) 61 were associated with increasing NAFLD severity in RNA-seq and proteomics data. Particularly, the QSOX1/IL1RAP ratio in plasma demonstrated effectiveness in 62 63 diagnosing NAFLD, with an area under the receiver operating characteristic (AUROC) 64 of up to 0.95 as quantified by proteomics profiling, and an AUROC of 0.82 with ELISA. 65 **Conclusions:** We discovered a significant association between the levels of QSOX1 66 and IL1RAP and NAFLD severity. Furthermore, the QSOX1/IL1RAP ratio shows promise as a non-invasive biomarker for diagnosing NAFLD and assessing its severity. 67

68

69

70 Lay Summary

71 This study aimed to find non-invasive biomarkers for non-alcoholic fatty liver disease 72 (NAFLD). Researchers utilized a new gene clustering method to analyze RNA-seq data 73 from 625 liver samples. The identified biomarkers were further validated using 74 plasma proteomics profiling, enzyme-linked immunosorbent assay (ELISA), and liver 75 immunohistochemical staining (IHC) in three separate groups of healthy controls and 76 NAFLD patients. The study revealed that the levels of QSOX1 were elevated while 77 IL1RAP levels were reduced with increasing severity of NAFLD. Importantly, the ratio 78 of QSOX1 to IL1RAP expression in plasma showed promise as a non-invasive 79 diagnostic tool for assessing the severity of NAFLD, eliminating the reliance on liver 80 biopsy.

81

82 Keywords

83 Non-alcoholic fatty liver disease, RNA sequencing data integration, non-invasive

84 biomarker, quiescin sulfhydryl oxidase 1, interleukin-1 receptor accessory protein

86 Graphical abstract



88

90 Introduction

Non-alcoholic fatty liver disease (NAFLD) is recognized as the hepatic manifestation
of the metabolic syndrome, with an estimated global prevalence of around 25-32% (1,
2). The severity of this liver disease ranges from Non-alcoholic Fatty Liver (NAFL) with
simple steatosis to Non-alcoholic Steatohepatitis (NASH) with inflammation and
fibrosis, which can progress to NASH-induced cirrhosis and increase the risk of
hepatocellular carcinoma (HCC).

97

98 Liver biopsy is currently the gold standard for histological diagnosis of NAFLD despite 99 its associated side effects such as pain, bleeding, and rare mortality. To address these drawbacks and reduce costs, there is still an unmet need for novel, precise, and 100 101 cost-effective imaging tools and non-invasive biomarkers (3). Moreover, non-invasive 102 biomarkers are highly needed for replacing repeated liver biopsies when assessing 103 liver histology during pharmacological interventions. Existing NAFLD biomarkers 104 primarily focus on steatosis (e.g., SteatoTest[™] or the lipid accumulation product), 105 inflammation (e.g., circulating keratin 18 fragments [CK18), soluble CD163) or fibrosis 106 (e.g., ELF, FibroTest or Pro-C3 tests) (4-8). Despite advancements in biomarker 107 technology, development, and evaluation, an ideal biomarker for the diagnosis, 108 prognosis, and assessment of treatment effects in NAFLD has yet to be identified.

109

110 The traditional RNA-seq analysis approach, which relies on established tools such as 111 edgeR (9), DESeq2 (10), and Cufflinks (11), primarily focuses on identifying 112 differentially expressed genes (DEGs) through pairwise comparisons (12). However, 113 for conditions like NAFLD, which involve a complex scoring system and a continuous 114 range of histological variations, this approach has its limitations. NAFLD doesn't 115 involve transitioning between distinct states but represents a dynamic progression through constant histopathological changes. Pairwise comparisons oversimplify the 116 117 intricate genetic alterations that occur throughout NAFLD's development. What's 118 required is a more advanced analytical method capable of capturing the gradual and

119 overlapping gene expression changes across the entire spectrum of NAFLD. Such an 120 approach would offer a comprehensive representation of NAFLD's complexity and 121 enhance our understanding of its progression. In recent years, advancements in 122 technologies such as RNA sequencing (RNA-seq), single-cell analysis, and spatial transcriptomics have provided deeper insights into the molecular and cellular 123 processes involved in NAFLD progression (13-15). Large-scale profiling efforts, 124 combined with targeted validation approaches, have led to the discovery of potential 125 biomarkers (16, 17). However, the majority of available RNA-seq data are derived 126 from smaller cohorts of NAFLD patients, which limits the comprehensive 127 understanding of NAFLD severity. 128

129

130 In this study, modularity optimization methods were utilized to cluster genes by 131 employing a graph-based strategy, taking into account the gene expression patterns throughout the progression of NAFLD. We propose that integrating and analyzing 132 133 these datasets with the unbiased gene-based profiling strategy will provide further insights into the molecular progression of NAFLD and the identification of biomarkers 134 135 associated with NAFLD severity. In the present study, we identified over 300 NAFLD biomarkers by integrating and analyzing RNA-seg data from 625 liver 136 137 samples, including their NAFLD activity scores (NAS) and fibrosis scores, along with public proteomics data. We further validated these findings in two 138 independent NAFLD cohorts, demonstrating the potential of the QSOX1/IL1RAP ratio 139 140 as a non-invasive biomarker for diagnosing NAFLD and assessing its severity.

141

142 Materials and methods

143

144 Data Collection

Genome-wide RNA-seq data of human NAFLD and associated healthy controls were collected from the NCBI GEO (<u>https://www.ncbi.nlm.nih.gov/gds</u>, access date until May 2022). Only datasets that provided detailed NAS and fibrosis scores were included for further investigation, including seven datasets (GSE105127(18),

149 GSE107650(19), GSE126848(20), GSE130970(21), GSE135251(22, 23), GSE162694(24),

and GSE167523(25). (Supplementary Table 1)

151

152 Data Normalization

The SRA-formatted data were converted into FASTQ format using 'SraToolkit' 153 154 (sratoolkit.2.8.2-1-centos linux64) (https://github.com/ncbi/sra-tools). Sequencing 155 reads were aligned to the hg19 UCSC RNA sequences Genome Reference Consortium 37 156 Build (GRCh37) 'bowtie2' Human using (bowtie2-2.2.5) (https://rnnh.github.io/bioinfo-notebook/docs/bowtie2.html). Only protein-coding 157 transcripts were considered, and Transcript Per Million (TPM) values were obtained 158 159 by transforming the mapped transcript reads using 'RSEM' (rsem-1.2.12) (https://github.com/deweylab/RSEM). Then, TPM values were then subjected to 160 161 Trimmed Mean of M-values (TMM) normalization across all samples using 162 'metasegR' (metasegR 1.12.2) (26). The data from various sources involved in this 163 study were integrated and log1p-transformed, followed by batch correction using the 'removeBatchEffect' function in the R package 'limma' 164 (limma 3.54.2) (https://kasperdanielhansen.github.io/genbioconductor/html/limma.html) 165 (27). 166 Subsequently, the data were expanded (10^{x}) for further analysis (Figure 1A).

167

168 **RNA-seq Data Analysis and Database Construction**

After normalization and batch correction, the RNA-seg data were subjected to 169 170 Principal Components Analysis (PCA) and unsupervised clustering using the R 'Seurat' (Seurat-4.3.0) 171 package (https://satijalab.org/seurat/articles/get_started.html). We utilized 172 the "LogNormalize" method for global-scaling normalization, which normalized the 173 174 feature expression measurements across different samples for each gene by the total 175 expression. The normalized values were multiplied by a scale factor (default: 176 10,000) and log1p-transformed. Subsequently, scaling was applied to the identified variable features (default: 2,000). PCA was then performed on the scaled data, with a 177 default setting of computing and storing 50 Principal Components (PCs). To cluster 178

the genes, we employed modularity optimization techniques using a graph-based
clustering approach. The dimensions of reduction were set to 1:20, and
the resolution parameter was set to 2.3 (28).

182

To show the gene expression variation during the development of NAFLD associated with both NAS and fibrosis scores, we generated an RNA-seq database using 'ShinyCell' (<u>https://github.com/SGDDNB/ShinyCell</u>). This database was deployed at <u>https://dreamapp.biomed.au.dk/NAFLD/</u>.

187

188 **Proteomics Data Collection and Analysis**

189 The proteomics cohort dataset (PXD011839) includes 10 healthy controls, 10 NAFLD 190 patients with normal glucose tolerance (NAFLD ngt), 10 NAFLD patients with type 2 191 diabetes (NAFLD T2D), and 10 NAFLD patients with cirrhosis (29). We performed the 192 statistical analysis R-4.3.0 the using on dataset (EV1, tab4) 193 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396370/bin/MSB-15-e8793-s003. x isx). The NAFLD ngt and NAFLD T2D groups were merged into a single NAFLD group, 194

195 resulting in three groups: healthy controls, NAFLD, and cirrhosis.

196

197 Similar to RNA-seq analysis, we used 'Seurat' (Seurat-4.3.0) and employed the 198 "LogNormalize" method for global-scaling normalization. This method normalized 199 the feature expression measurements across different samples for each protein by 200 the total expression. The normalized values were multiplied by a scale factor (default: 201 10,000) and log1p-transformed. Subsequently, scaling was applied to the identified 202 variable features (default: 2,000). PCA was performed on the scaled data, with a total 203 of 39 Principal Components (PCs) computed and stored. Additionally, we calculated 204 the log fold-change of the average expression between two groups (avg log2FC) by 205 comparing the health and NAFLD groups, as well as the NAFLD and cirrhosis groups. 206 By setting avg $\log 2FC > 0$, we selected up- and down-regulated proteins associated with increasing severity of NAFLD. 207

209 Validation of QSOX1 and IL1RAP as Biomarkers in NAFLD

Our objective was to investigate whether *QSOX1* and *IL1RAP* gene expression levels, as well as their encoded proteins, could predict the histological severity of NAFLD. To address this question, we examined the plasma concentrations of QSOX1 and IL1RAP in the proteomics data of healthy and NAFLD cohorts. Additionally, we conducted enzyme-linked immunosorbent assay (ELISA) tests for plasma QSOX1/IL1RAP in a cohort comprising healthy subjects and NAFLD patients recruited at Shenzhen Traditional Chinese Medicine Hospital, China (SZTCMH).

217

218 Human Samples

219 A total of 28 ultrasound-proven adult NAFLD patients, including NAFLD ngt and 220 NAFLD T2D, and 14 healthy controls were enrolled from SZTCMH. Other diagnoses 221 and etiologies, such as excessive alcohol consumption, viral hepatitis, autoimmune 222 liver disease, and the use of steatogenic compounds, were excluded. Archived 223 plasma samples were collected between October and December 2022. Informed 224 consent was obtained from the healthy subjects and NAFLD patients, following the 225 approved clinical protocols of the Ethical Committee of SZTCMH. Clinical information, including body mass index (BMI) and standard biochemistry (liver, kidney, 226 227 hematology) with metabolic profiling (glucose, insulin, lipids), was collected. Fibroscan with controlled attenuation parameter (CAP) values was performed to 228 assess fibrosis and steatosis. Clinical information for the healthy controls and NAFLD 229 230 patients can be found in **Supplementary Table 5**.

231

For immunohistochemical staining (IHC), 12 fixed liver tissues were collected from archived histological samples at SZTCMH between 2014 and 2023. These samples were scored based on the NAS score (N0 to N8) and fibrosis score (F0 to F4) by two pathologists (MMS and XWY). Six samples were from mild NAFLD patients (N0-4, F0-2), and six were from severe NAFLD patients (N5-8, F3-4). The clinical study was approved by the Ethical Committee of SZTCMH, and the approved clinical protocols adhere to the Helsinki Declaration (No. K2022-174-01).

239

240 **ELISA**

241 Blind ELISA tests were conducted on the collected plasma samples. Randomly 242 assigned sample identifiers and positions were used to ensure blindness to the 243 clinical information and NAFLD stages. The levels of QSOX1 and IL1RAP were measured using QSOX1 ELISA Kits (Catalog No. YJ145587, Lot No. 12/2022 from 244 245 Enzyme-linked Biotechnology, Shanghai, China) and IL1RAP ELISA Kits (Catalog No. YJ130558, Lot No. 12/2022 from Enzyme-linked Biotechnology, Shanghai, China), 246 respectively. The measurements followed the manufacturer's instructions and the 247 absorbance values were measured at 450nm. To ensure the reliability of the ELISA 248 249 Kits, a pre-experiment was conducted three times before the formal experiment.

250

251 Immunohistochemisgtry Assay

252 We examined the association of QSOX1 and IL1RAP with human NAFLD severity by 253 performing IHC on formalin-fixed and paraffin-embedded liver sections from 6 mild 254 NAFLD patients and 6 severe NAFLD patients. The 3 µm-thick paraffin sections were 255 deparaffinized and rehydrated with distilled water. Antigen retrieval was carried out 256 using pH 9.0 EDTA buffer, followed by 20 minutes of boiling and washing with 1X PBS. 257 Subsequently, the slides were blocked with 1% bovine serum albumin in 1X PBS for 15 minutes and then incubated overnight at 4° C with QSOX1 (Rabbit anti-human, 258 259 Catalog No. Ab235444, Lot No. GR3386311-2 from Abcam) or IL1RAP (Rabbit 260 anti-human, Catalog No.35605, Lot No. 4926 from Sabbiotech) antibodies at a 261 concentration of 20 μ g/ml. The following day, the slides were washed with 1X PBS 262 and incubated with Goat anti-rabbit IgG H&L (Catalog No. Ab205718, Lot No. 263 ab205718 from Abcam) for 15 minutes at room temperature, followed by another 264 wash with 1X PBS. The images were captured using a light microscope and 265 3DHISTECH digital scanner (https://www.3dhistech.com/).

266

267 The IHC results were analyzed using the software tool 'ImagineJ (Fiji)'. To prevent

potential bias, we randomly selected five locations of the same size from each 268 269 sample at 20x magnification using **3DHISTECH** CaseViewer 2.4 270 (https://www.3dhistech.com/solutions/caseviewer/). Using 'ImagineJ', we applied the "Colour Deconvolution" tool with vectors=[H DAB]; followed by selecting the 271 Colour 2 pictures and running "8-bit". Standard thresholds were used (QSOX1: 272 setThreshold (60, 230), IL1RAP: setThreshold (94, 214)) (30, 31). The average 273 274 integrated density from the five sites was calculated and used as the integrated 275 density value for each sample, which was then subjected to statistical analysis.

276

277 Statistical analysis

- 278 The significance for all statistical tests was two-sided, with P < 0.05. All data analysis
- was presented in the plots using R-4.3.0, and MedCalc was used to calculate the
- AUROC, sensitivity, specificity, optimal cutoff value, and sample size.

281 Results

282 Overview of RNA-seq data and NAFLD patient cohorts

283 After applying stringent filtering criteria based on the availability of histological NAS 284 and fibrosis scores, five datasets including GSE115193 (32), GSE134422 (33), GSE135448 (34), GSE160016 (35), and GSE164441 (36) were excluded from the 285 286 analysis, while seven datasets (GSE105127 (18), GSE107650 (19), GSE126848 (20), 287 GSE130970 (21), GSE135251 (22, 23), GSE162694 (24), and GSE167523 (25)) were 288 included. These datasets collectively comprise 81 healthy controls (including healthy 289 obsese individuals) (NOFO) and 544 NAFLD patients. The severity of NAFLD patients 290 was classified based on the NAS score (ranging from N1 to N8) and the fibrosis score 291 (ranging from F0 to F4) using the scoring systems proposed by Brunt (37) and Kleiner 292 (38), respectively (Table 1, Supplementary Table 1). A positive correlation was observed between NAS and fibrosis scores (Pearson R = 0.64, P = 4.94E-74, Table 1), 293 294 indicating an association with NAFLD severity.

295

296 Normalization and Integration of RNA-seq Data

297 To address the issue of batch effects resulting from differences in sequencing 298 technology and studies, we processed the integrated data as depicted in Figure 1A. 299 Genes with low expression were filtered out, resulting in a total of 17,946 300 protein-coding genes. Principal component analysis (PCA) demonstrated that 301 normalization effectively eliminated noticeable batch effects (Figure 1B). Moreover, 302 neither the NAS nor fibrosis scores appeared to be the main factors contributing to 303 sample separation (Figure 1D, E). Instead, the normalized RNA abundance (nCount) 304 in each sample emerged as the key component influencing transcriptome profiles 305 (Figure 1C).

306

307 Unsupervised Gene Clustering Identifies Clusters of Genes Associated with NAFLD
 308 Severity.

309 To identify genes associated with NAFLD severity, we utilized a previously developed

310 unsupervised gene clustering method based on the similarity of gene expression 311 patterns across each sample (39). We employed gene clustering, grouping genes according to their expression patterns during the progression of NAFLD. By setting a 312 313 resolution of 2.3, we identified a total of 37 gene clusters (Supplementary Figure S1). Notably, cluster 4, consisting of 1021 genes, consistently exhibited increased 314 expression with higher NAS and fibrosis scores (Figure 2A, Supplementary Figure 315 **S2A**). Conversely, cluster 14, comprising 643 genes, showed decreased expression 316 with increasing NAS and fibrosis scores (Figure 2B, Supplementary Figure S2B). As 317 illustrated in figures (Figure 2A, B, Supplementary Figure S2A, B, C, D), this approach 318 efficiently clustered genes into distinct groups based on their expression patterns 319 320 across NAFLD severity stages. It offers a more structured depiction of gene 321 expression variations, enabling a deeper understanding of NAFLD's molecular 322 pathogenesis. Through visualizing and categorizing these gene expression changes, we can acquire a more comprehensive insight into the underlying mechanisms and 323 324 factors that propel NAFLD progression.

325

326 To explore the biological functions of these gene clusters, we performed Gene 327 Ontology (GO) analysis using the R package 'ClusterProfiler' (ClusterProfiler-4.8.0). 328 Specifically, we focused on cluster 4, which consisted of up-regulated genes. The GO analysis revealed significant enrichment of genes involved in the fibrosis-related 329 process, such as extracellular matrix (ECM) organization (p.adjust = 9.77E-34), 330 extracellular structure organization (p.adjust = 9.77E-34), external encapsulating 331 structure organization (p.adjust = 1.09E-33), and cell-substrate adhesion (p.adjust = 332 3.35E-17). Notably, the expression of multiple genes involved in the ECM processes, 333 such as COL5A3, FBLN5, SPINT2, COL1A1, COL1A2, COL3A1, COL4A1, COL4A4, 334 335 COL12A1, COL15A1, and COL16A1, showed a gradual up-regulation during the 336 progression of NAFLD (Figure 2A, Supplementary Figure S3).

337

In contrast, cluster 14, which displayed a reverse correlation with NAS and fibrosis
scores, was significantly enriched in metabolic processes, indicating an association

340 between NAFLD progression and attenuated liver metabolism. The down-regulated 341 genes in this cluster were particularly enriched in processes such as organic acid 342 catabolic process (p.adjust = 2.57E-22), carboxylic acid catabolic process (p.adjust = 343 2.57E-22), small molecule catabolic process (p.adjust = 5.28E-22), alpha-amino acid metabolic process (p.adjust = 6.03E-20), fatty acid metabolic process (p.adjust = 344 2.60E-10), and alcohol metabolic process (p.adjust = 1.35E-09). Notably, genes 345 encoding enzymes of the Cytochrome P450 superfamily, including CYP1A2, CYP2C19, 346 CYP2J2, CYP2E1, CYP4A11, CYP4A22, CYP4F11, CYP2C8, and CYP3A4, were 347 down-regulated with increasing NAFLD severity (Figure 2B, Supplementary Figure 348 **S4**). For a comprehensive list of all enriched GO terms for genes in cluster 4 and 14, 349 350 please refer to Supplementary Table 2.

351

In addition, we developed a NAFLD gene expression database (NAFLD-DB) to facilitate the exploration and comparison of all identified protein-coding genes based on NAFLD severity. The NAFLD-DB (<u>https://dreamapp.biomed.au.dk/NAFLD/</u>) was constructed using the ShinyCell framework (40), which was specifically designed for convenient exploration and sharing of single-cell transcriptome data.

357

358 Identification of Candidate Diagnostic Biomarkers

We employed an additional complementary strategy to further refine our list of candidate genes. In this approach, we first analyzed the plasma protein levels from a NAFLD cohort in a proteomics dataset (PXD011839) (29). We selected proteins that showed positive correlations with increasing NAFLD severity (avg_log2FC > 0) and proteins that showed negative correlations. As a result, we identified 148 up-regulated proteins and 114 down-regulated proteins associated with increasing NAFLD severity (**Figure 2C, D**).

366

The secretome, which consists of secreted proteins, has emerged as a valuable resource for disease diagnostics (41-43). In our study, we aim to identify potential diagnostic markers among the candidate genes, by comparing our gene clusters with

the secretome database from the Human Protein Atlas (44). This cross-analysis revealed a total of 349 genes encoding secreted proteins, with 249 genes showing up-regulation and 100 genes showing down-regulation (**Figure 2E**). Notably, our approach successfully identified a comprehensive list of previously known NAFLD diagnostic and prognostic markers, including *ADAMTSL2* (45), *AEBP1* (46), and *BGN* (47) (**Supplementary Table 3**), further validating the effectiveness of our approach.

376

Next, we intersected the protein-encoding genes of these proteins with the 377 secretome genes and the candidate genes generated from our RNA-seg analysis. 378 Through this cross-comparison, we identified 16 up-regulated secreting genes (A2M, 379 380 C7, COL6A3, COLEC11, ENPP2, FBLN1, FBN1, FCGBP, IGFBP6, LCN2, LUM, MMP2, 381 PAPLN, PTGDS, QSOX1, VWF) and 22 down-regulated secreting genes (AZGP1, C1RL, 382 C4BPA, C6, C8B, CFHR3, CNDP1, F2, GC, HP, HPR, IL1RAP, ITIH1, ITIH2, ITIH4, KLKB1, PON3, SERPINA10, SERPINC1, SERPING1, SMPDL3A, TTR) associated with increasing 383 384 NAFLD severity in both the RNA-seg and proteomics data (Supplementary Figure S5). 385

386 **QSOX1 and IL1RAP are promising biomarkers for NAFLD severity**

387 To demonstrate the applicability of our NAFLD-DB and validate the association of 388 differential gene expression with increasing NAFLD severity, we selected two representative genes, QSOX1 and IL1RAP, which showed positive and negative 389 correlations with increasing NAFLD severity, and their roles as biomarkers were 390 under explored as compared to other NAFLD biomarkers (Supplementary Figure S5). 391 392 We examined their expression levels in comparison to patients with a NAS or fibrosis 393 score of 0 (N0 or F0). The expression of QSOX1 was significantly correlated with the severity of NAFLD compared to NO or FO patients: N1-4 (p = 0.003), N5-8 (p =394 395 1.9E-10), F1-2 (p = 0.001), F3-4 (p = 6.5E-8) (Figure 3A, B). On the other hand, IL1RAP 396 expression was significantly lower in patients with increased NAFLD severity compared to N0 or F0: N1-4 (p = 1E-5), N5-8 (p = 4.7E-10), F1-2 (p = 0.00012), F3-4 (p397 = 0.00013) (Figure 3C, D). 398

399

Since *QSOX1* and *IL1RAP* exhibited opposite correlations with NAFLD severity, we further explored whether the ratio of QSOX1/IL1RAP could better distinguish between patient groups. Our results showed that compared to NO or FO patients, the ratio of QSOX1 to IL1RAP mRNA levels showed even greater separation: N1-4 (p = 7.6E-8), N5-8 (5.9E-16), F1-2 (4.6E-6), F3-4 (6.8E-8) (**Figure 3E, F**). These findings suggest that the QSOX1/IL1RAP ratio has the potential as a biomarker for diagnosing NAFLD severity.

407

Validation of Plasma QSOX1/IL1RAP Levels as Biomarkers for NAFLD Severity with NAFLD Proteomics Cohort

410 To further validate the potential of QSOX1 and IL1RAP as biomarkers for NAFLD 411 severity, we analyzed the plasma levels of QSOX1 and IL1RAP in a NAFLD proteomics 412 cohort (PXD011839) previously conducted by Niu L and colleagues (29). Consistent with our liver RNA profiling results in livers, the analysis of plasma proteomics data 413 414 from this independent NAFLD cohort showed a significant increase in plasma QSOX1 415 levels in patients with NAFLD (Wilcoxon rank sum test, p = 0.021) and cirrhosis (p =416 0.049) compared to healthy controls (Figure 4A). Conversely, IL1RAP levels were 417 significantly reduced in patients with NAFLD (p = 5.8E-5) and cirrhosis (p = 0.0011) 418 (Figure 4B). Moreover, when considering the combined marker of plasma QSOX1/IL1RAP ratio, it demonstrated even greater significance in distinguishing 419 420 NAFLD (p = 9.3E-6) and cirrhosis (p = 0.00013) patients from the control group, 421 compared to using QSOX1 or IL1RAP alone (Figure 4C).

422

To access the diagnostic sensitivity and specificity of QSOX1, IL1RAP, and their ratio for NAFLD severity, we conducted ROC curve analysis using the 'MedCalc' tool (30). The sample sizes for each comparison were evaluated and are listed in **Supplementary Table 4**. The AUROC of the QSOX1/IL1RAP ratio for distinguishing NAFLD patients from healthy controls was 0.95, with a cutoff value of 1.12. The sensitivity was determined to be 90%, and the specificity was 100%. Notably, the efficacy of the QSOX1/IL1RAP ratio was superior to that of IL1RAP alone

(AUROC=0.92) or QSOX1 alone (not significant). Similarly, when assessing the
differentiation between cirrhosis patients and healthy controls, the AUROC of the
QSOX1/IL1RAP ratio was 0.96, with a cutoff value of 1.12. The sensitivity was 90%,
and the specificity was 100%.

434

These results indicate that the QSOX1/IL1RAP ratio holds promise as a highly effective biomarker for diagnosing NAFLD severity, surpassing the individual biomarkers alone, and maintaining better sensitivity and specificity in distinguishing NAFLD patients and cirrhosis patients from healthy individuals.

439

Validation of QSOX1 and IL1RAP as biomarkers for NAFLD in another patient cohort To further validate the utility of QSOX1 and IL1RAP as biomarkers for NAFLD, we conducted a validation study in healthy controls and NAFLD patients recruited from the Department of Liver Disease of Shenzhen Traditional Chinese Medicine Hospital. Plasma samples were collected from 14 healthy subjects and 28 newly diagnosed NAFLD patients. Clinical information for the healthy controls and NAFLD patients can be found in **Supplementary Table 5**.

447

We measured plasma levels of QSOX1 and IL1RAP using an enzyme-linked immunosorbent assay (ELISA). Consistent with our previous findings, plasma levels of QSOX1 (Wilcoxon rank sum test, p = 0.043), IL1RAP (p = 0.035), and the QSOX1/IL1RAP ratio (p = 0.00061) were significantly different between NAFLD patients and controls (**Figure 4D, E, F**).

453

To assess the diagnostic value of QSOX1 and IL1RAP as non-invasive biomarkers for NAFLD by ELISA, we calculated the AUROC of the QSOX1/IL1RAP ratio in the ELISA test to distinguish NAFLD patients from healthy controls. The QSOX1/IL1RAP ratio exhibited an AUROC of 0.82. Using a cutoff of 0.05, the sensitivity was 93% and the specificity was 57%. In comparison, the AUROC of QSOX1/IL1RAP ratio quantified by ELISA showed less efficacy in distinguishing NAFLD patients from healthy controls

460 (Supplementary Table 4), which may be attributed to the sensitivity of protein
461 quantification methods and small sample size.

462

To further validate the association between QSOX1 and IL1RAP protein levels and 463 NAFLD severity, we assessed their levels in liver biopsies from mild and severe NAFLD 464 patients using IHC. Our results consistently demonstrated a significant correlation 465 466 between QSOX1 and IL1RAP levels and NAFLD severity (Figure 5A). Quantification of 467 QSOX1 and IL1RAP levels based on IHC confirmed that the QSOX1/IL1RAP ratio (p =0.027) could distinguish the severe NAFLD group (n=6; NAS 5-8, fibrosis score 3-4) 468 469 from the mild NAFLD group (n=6; NAS 0-4, Fibrosis score 0-2) (Figure 5B, C). 470 Collectively, these findings suggest that the QSOX1/IL1RAP ratio holds promise as an effective biomarker for the early diagnosis and prediction of NAFLD severity. 471

472 **Discussion**

473 This study is the first to integrate publicly available RNA-seq datasets from over 600 474 NAFLD patients with varying stages of disease severity, combined with proteomics 475 data analysis of publicly available datasets. The key findings suggest that the 476 QSOX1/IL1RAP, and particularly the QSOX1/IL1RAP ratio hold promise as potential 477 biomarkers for NAFLD severity assessment. These results align with recent research 478 highlighting the importance of different transcriptional profiles specific to NAS and 479 fibrosis scores, offering valuable insights into the molecular mechanisms driving 480 disease progression from simple steatosis to inflammation and fibrosis (21, 24).

481

482 The Advantages of Utilizing Integrated RNA-seq Data for Investigating NAFLD 483 Biomarkers

484 Despite the growing availability of RNA-seq data in this field, many original studies 485 have been limited by small sample sizes and biased sample distribution, making it 486 challenging to accurately decipher transcriptional differences across various stages of 487 NAFLD(18, 20-22, 24). Several studies have attempted to identify diagnostic 488 biomarkers and potential drug targets. For instance, Brosch et al. conducted a 489 positional analysis of transcriptomes across three micro-dissected liver zones from 19 490 NAFLD patients (18). Suppli et al. demonstrated that immunohistochemical markers offer greater objectivity in distinguishing hepatocyte injury between NASH and NAFL 491 492 (20). In the pursuit of diagnostic genes and novel drug targets, Hoang et al. studied 6 493 histologically normal and 72 NAFLD patients, while Pantano et al. studied 31 494 histologically normal and 112 NAFLD patients. These studies revealed that specific 495 cells proportion and candidate gene signatures can accurately predict fibrosis stage 496 and disease progression (21, 24). Likewise, Govaere et al. observed the correlation 497 between gene expression and histology in a cohort of 10 controls and 206 NAFLD 498 patients (22). In contrast to the studies above that identified sets of potential 499 biomarker genes, Kozumi et al. validated thrombospondin 2 (THBS2) as a noninvasive 500 biomarker for NAFLD. They confirmed its potential in identifying the disease stages

501 among 98 NAFLD patients, and the serum levels of its encoded protein TSP-2, 502 measured by ELISA, showed an AUROC of 0.78 in the diagnosing of NASH among 213 503 patients with biopsy-proven NAFLD (25). The major challenge of combining and 504 analyzing these diverse datasets lies in achieving homogeneous processing, which 505 requires substantial time and computational resources (48, 49). To generate more 506 robust and compelling results, we employed unbiased integration of comprehensive 507 NAFLD data to profile the liver transcriptome across a broad spectrum of NAFLD severity in our study, incorporating all the aforementioned samples. 508

509

510 The Superiority of QSOX1 and IL1RAP as Potential Biomarkers of NAFLD

511 The high prevalence and associated risks of NAFLD have driven global efforts to 512 identify improved diagnostic biomarkers. However, most existing biomarkers are 513 primarily suited for evaluating fibrosis (3, 50-52). The Fibrosis-4 (FIB-4) test 514 commonly used in clinical practice, is sub-optimal for screening purposes, as it carries 515 the risks of both overdiagnosis and false negatives, particularly in patients at risk of 516 chronic liver disease (8). Although the patented ELF[™] test was highly recommended 517 for ruling out advanced fibrosis, it comes with higher costs. Several steatosis scores, 518 such as the SteatoTest[™] and the fatty liver index (FLI), have been proposed for 519 steatosis detection, but they do not provide substantial additional information 520 beyond routine clinical, laboratory, and imaging examinations conducted in patients suspected of having NAFLD(8). Non-coding RNAs (ncRNAs), which exhibit 521 522 aberrant expression associated with NAFLD, have emerged as potential biomarkers 523 for NAFLD pathology, and circulating ncRNAs including miR-122 and lncRNAs are proposed as potential biomarkers for NAFLD severity and progression (53-59). 524 525 Despite the development of new biomarkers, there is still uncertainty surrounding 526 their predictive value, underscoring the urgent need to develop novel, cost-effective, 527 and efficient biomarkers with high sensitivity and specificity for NAFLD prediction and monitoring (4, 60). 528

529

530 The approach by Hoang et al. (21) centered on identifying genes with diverse

531 expressions associated with NAFLD severity, inspired us to develop our gene 532 clustering method. Our approach surpasses the constraints of conventional RNA-seq data analysis, which predominantly relies on pairwise comparisons. Instead, it 533 534 classifies genes according to their dynamic expression patterns, enabling a more 535 comprehensive and dynamic perspective of molecular alterations as NAFLD progresses. This method has the potential to map NAFLD severity and progression 536 solely through gene expressions, thus avoiding invasive procedures like liver biopsies. 537 Moreover, the gene-based scoring system can forecast NAFLD progression, 538 facilitating early interventions for patients at risk of advancing to severe disease 539 540 stages.

541

542 Previous studies have explored the relationship between QSOX1, IL1RAP, and NAFLD 543 or steatosis(16, 61). QSOX1 has been suggested as a potential diagnostic biomarker for NAFLD, playing a significant role in lipid metabolism as an enzyme expressed in 544 545 various tissues, particularly in guiescent fibroblasts (18, 62, 63). IL1RAP is localized in 546 vesicles and cytosol, and it is secreted into the bloodstream. Notably, IL1RAP 547 expression at the RNA level was specifically detected in the liver and hepatocytes 548 (44). Hence, the combination of QSOX1 and IL1RAP as secretome genes and proteins 549 was selected as a potential biomarker combination.

550

The potential of QSOX1, IL1RAP, and their ratio as biomarkers for NAFLD was demonstrated through the analysis of public RNA-seq and proteomics data, ELISA tests conducted on patients' plasma, and IHC performed on fixed liver slides. These findings suggest that QSOX1, IL1RAP, and their ratio hold promise as effective biomarkers for NAFLD. Notably, the higher AUROC values for NAFLD diagnosis achieved by QSOX1, IL1RAP, and their ratio highlight their efficacy as NAFLD biomarkers.

558

559 Limitation and Future Prospects.

560 The current study possesses several strengths, including the integration and

561 processing of RNA-seq data from over 600 NAFLD patients with varying degrees of 562 NAFLD severity, as well as validation using proteomics data and samples from NAFLD 563 patients and controls. Furthermore, the well-established database with a 564 user-friendly interface could benefit the research community in exploring 565 differentially expressed genes in NAFLD at various stages. However, there are also limitations to consider. For instance, some samples in the GSE126848 and GSE167523 566 datasets lacked individual NAS and fibrosis scores. To address this issue, 567 we standardized scores based on their categories in the original articles, and the 568 impact on the results was deemed negligible due to the provision of general stages 569 and unsupervised gene clustering. Machine learning, an essential tool for biomarker 570 571 validation and sample classification validation, should be employed to train large 572 cohorts of biopsy-proven NAFLD patients and healthy controls. However, this would 573 require an extended recruiting period (64) to determine the sensitivity and specificity 574 of the QSOX1/IL1RAP ratio for NAFLD diagnosis and staging.

575

Although newer technologies such as single-cell RNA sequencing (scRNA-seq) and 576 577 spatial sequencing have gained popularity, RNA-seq still serves as a valuable tool in 578 uncovering the pathogenesis of NAFLD (17). Computational analysis limitations make 579 it impractical for large cohort research, and single-cell suspension processing may affect cell abundance and cell type representation, particularly in hepatic ballooning 580 cells in NAFLD (65). Single-nuclei RNA sequencing (snRNA-seq) captures cell 581 frequency more accurately than scRNA-seq but captures lower gene expression. 582 Spatial transcriptomics and proteomics have limitations for discovering invasive 583 584 biomarkers of NAFLD as they focus on small sampling areas (15). The combination of all these biological tools holds potential for future research. 585

586

In conclusion, through a novel approach of unsupervised gene clustering performed on integrated RNA-seq data, we have discovered a significant association between QSOX1 and IL1RAP levels and NAFLD severity, with their ratio showing potential as a non-invasive biomarker for diagnosing and assessing the severity of NAFLD.

Validation of our plasma-level findings in larger cohorts of liver biopsies is required, but it holds promise as a new tool to diagnose NAFLD severity and reduce the need for liver biopsies. Our approach may lead to the discovery of more NAFLD biomarkers, and the ratios of other up-regulated and down-regulated genes associated with increasing NAFLD severity also have the potential to be verified as potential biomarkers.

597

598 Abbreviations

599 AUROC, area under the receiver operating characteristic; avg log2FC, log fold-change 600 of the average expression between the two groups; BMI, body mass index; CK18, 601 circulating keratin 18 fragments; ECM, extracellular matrix; ELISA, enzyme-linked 602 immunosorbent assay; F, Fibrosis score; FIB-4, Fibrosis-4; GEO, Gene Expression 603 Omnibus; GO, Gene Ontology; GRCh37, Genome Reference Consortium Human Build 604 37; HCC, hepatocellular carcinoma; IHC, immunohistochemistry staining; IL1RAP, 605 Interleukin-1 receptor accessory protein; lg, log10; PCA, Principal components 606 analysis; QSOX1, Quiescin sulfhydryl oxidase 1; RNA-seq, RNA sequencing; N, NAS 607 score; NAFL, Non-alcoholic Fatty Liver; NAFLD, Non-alcoholic fatty liver disease; 608 NAFLD-DB, NAFLD gene expression database; NAFLD ngt, NAFLD with normal 609 glucose tolerance; NAFLD T2D, NAFLD with type 2 diabetes; NAS, NAFLD activity 610 scores; NASH, Non-alcoholic Steatohepatitis; ncRNAs, non-coding RNAs; scRNA-seq, 611 single-cell RNA sequencing; snRNA-seq, Single-nuclei RNA sequencing; SZTCMH, 612 Shenzhen Traditional Chinese Medicine Hospital, China; THBS2, thrombospondin 2; 613 TMM, Trimmed Mean of M-values; TPM, Transcript Per Million.

614

615 **Financial support**

This research was funded by the Shenzhen Science and Technology Project and Sanming Project of Medicine in Shenzhen, China (grant nos. SZSM201612074, JCYJ20210324120405015).

619

620 Authors' contributions

- YLL, HG, WFM and LL designed the study and interpreted the data. The analysis
 strategy has been developed by LL and WFM. WFM, JRH, BQC, MLL, XZ, SMX and
 MBK collected and assembled the data. WFM drafted the manuscript. WFM, JRH and
 LC performed data analysis and/or interpretation. Technical support: YLL, LL, JRH, ZXZ,
 MMS and XWY. Study participant inclusion: ZXZ, WFM, BQC, MLL, XZ, SMX, BLZ, QL,
 QH, MQM. All authors reviewed and approved the final version of the manuscript.
- 627

628 Data and code availability statement

- 629 The data that support the findings of this study are available from the corresponding
- 630 author upon reasonable request.
- 631

632 **Conflict of interest**

- 633 Henning Grønbæk has received research grants from Abbvie, Intercept, ARLA Food
- 634 for Health, ADS AIPHIA Development Services AG. Consulting Fees from Ipsen, NOVO,
- 635 Pfizer. Lecturer for AstraZeneca and EISAI; and on Data Monitoring Committee at
- 636 CAMURUS AB. All other authors have no conflicts of interest to declare.

637

638 **Reference**

Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, et al.
Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol
Hepatol 2022;19:60-78.

Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, et al. The prevalence
and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol
Hepatol 2022;7:851-861.

645 3. Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12.

Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical
prediction rules and blood-based biomarkers. J Hepatol 2018;68:305-315.

Kazankov K, Barrera F, Moller HJ, Rosso C, Bugianesi E, David E, Younes R, et al. The macrophage
activation marker sCD163 is associated with morphological disease stages in patients with
non-alcoholic fatty liver disease. Liver Int 2016;36:1549-1557.

6. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past,
present and future. J Hepatol 2022;76:1362-1378.

653 7. Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9.

654 8. European Association for the Study of the Liver. Electronic address eee, Clinical Practice

655 Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests

for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-689.

857 9. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression
858 analysis of digital gene expression data. Bioinformatics 2010;26:139-140.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seqdata with DESeq2. Genome Biol 2014;15:550.

11. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, et al. Differential gene and
transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc
2012;7:562-578.

664 12. Costa-Silva J, Domingues DS, Menotti D, Hungria M, Lopes FM. Temporal progress of gene
665 expression analysis with RNA-Seq data: A review on the relationship between computational methods.
666 Comput Struct Biotechnol J 2023;21:86-98.

667 13. Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD - more than
668 inflammation. Nat Rev Endocrinol 2022;18:461-472.

4. Wang ZY, Keogh A, Waldt A, Cuttat R, Neri M, Zhu S, Schuierer S, et al. Single-cell and bulk
transcriptomics of the liver reveals potential targets of NASH with fibrosis. Sci Rep 2021;11:19396.

671 15. Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, Bujko A, et al. Spatial

proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell
2022;185:379-396 e338.

674 16. Green CD, Dozmorov MG, Spiegel S. Analysis of Liver Responses to Non-alcoholic Steatohepatitis
675 by mRNA-Sequencing. Methods Mol Biol 2022;2455:163-179.

676 17. Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet677 2019;20:631-656.

Brosch M, Kattler K, Herrmann A, von Schonfels W, Nordstrom K, Seehofer D, Damm G, et al.
Epigenomic map of human liver reveals principles of zonated morphogenic and metabolic control. Nat
Commun 2018;9:4150.

Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A, Rasanen SM, Lee S, et al. An Integrated
Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis
in Humans. Cell Metab 2018;27:559-571 e555.

Suppli MP, Rigbolt KTG, Veidal SS, Heeboll S, Eriksen PL, Demant M, Bagger JI, et al. Hepatic
transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared
with healthy normal-weight individuals. Am J Physiol Gastrointest Liver Physiol 2019;316:G462-G472.

687 21. Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, et al. Gene
688 Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty
689 Liver Disease. Sci Rep 2019;9:12541.

690 22. Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, et al. Transcriptomic
691 profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for
692 steatohepatitis and fibrosis. Sci Transl Med 2020;12.

693 23. Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, et al. NASH limits
694 anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-456.

695 24. Pantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, Knebel D, et al. Molecular

696 characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 2021;11:18045.

697 25. Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, et al. Transcriptomics
698 Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology
699 2021;74:2452-2466.

700 26. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling,

and transformations: improving the biological information content of metabolomics data. BMC
 Genomics 2006;7:142.

703 27. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential
704 expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.

705 28. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, Lee MJ, et al. Integrated
706 analysis of multimodal single-cell data. Cell 2021;184:3573-3587 e3529.

707 29. Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, et al. Plasma
708 proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst
709 Biol 2019;15:e8793.

30. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat
Methods 2012;9:671-675.

31. Shu J, Dolman GE, Duan J, Qiu G, Ilyas M. Statistical colour models: an automated digital image
analysis method for quantification of histological biomarkers. Biomed Eng Online 2016;15:46.

714 32. Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical Models for Studying
715 NASH-Driven HCC: How Useful Are They? Cell Metab 2019;29:18-26.

716 33. Florentino RM, Fraunhoffer NA, Morita K, Takeishi K, Ostrowska A, Achreja A, Animasahun O, et
717 al. Cellular Location of HNF4alpha is Linked With Terminal Liver Failure in Humans. Hepatol Commun
718 2020;4:859-875.

Xu C, Markova M, Seebeck N, Loft A, Hornemann S, Gantert T, Kabisch S, et al. High-protein diet
more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels.
Liver Int 2020;40:2982-2997.

35. Hou J, Zhang J, Cui P, Zhou Y, Liu C, Wu X, Ji Y, et al. TREM2 sustains macrophage-hepatocyte
metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest 2021;131.

Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, Tang W, et al. A selective HDAC8 inhibitor
potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular
carcinoma. Sci Transl Med 2021;13.

727 37. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic
728 steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol
729 1999;94:2467-2474.

730 38. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design
731 and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology
732 2005;41:1313-1321.

733 39. Karlsson M, Sjostedt E, Oksvold P, Sivertsson A, Huang J, Alvez MB, Arif M, et al. Genome-wide
734 annotation of protein-coding genes in pig. BMC Biol 2022;20:25.

40. Ouyang JF, Kamaraj US, Cao EY, Rackham OJL. ShinyCell: Simple and sharable visualisation of
single-cell gene expression data. Bioinformatics 2021.

41. Liu Y, Ciotti GE, Eisinger-Mathason TSK. Hypoxia and the Tumor Secretome. Adv Exp Med Biol
2019;1136:57-69.

739 42. Crescenzi E, Leonardi A, Pacifico F. NGAL as a Potential Target in Tumor Microenvironment. Int J
740 Mol Sci 2021;22.

741 43. Zhou X, Zhang J, Lv W, Zhao C, Xia Y, Wu Y, Zhang Q. The pleiotropic roles of adipocyte secretome

in remodeling breast cancer. J Exp Clin Cancer Res 2022;41:203.

44. Uhlen M, Karlsson MJ, Hober A, Svensson AS, Scheffel J, Kotol D, Zhong W, et al. The human
secretome. Sci Signal 2019;12.

745 45. Corey KE, Pitts R, Lai M, Loureiro J, Masia R, Osganian SA, Gustafson JL, et al. ADAMTSL2 protein

and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults

747 with NAFLD. J Hepatol 2022;76:25-33.

46. Gerhard GS, Hanson A, Wilhelmsen D, Piras IS, Still CD, Chu X, Petrick AT, et al. AEBP1 expression
increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p.
PLoS One 2019;14:e0219764.

47. Cengiz M, Yilmaz G, Ozenirler S. Serum Biglycan as a Diagnostic Marker for Non-Alcoholic
752 Steatohepatitis and Liver Fibrosis. Clin Lab 2021;67.

753 48. Stupnikov A, McInerney CE, Savage KI, McIntosh SA, Emmert-Streib F, Kennedy R, Salto-Tellez M,

et al. Robustness of differential gene expression analysis of RNA-seq. Comput Struct Biotechnol J
2021;19:3470-3481.

49. Shakola F, Palejev D, Ivanov I. A Framework for Comparison and Assessment of Synthetic
757 RNA-Seq Data. Genes (Basel) 2022;13.

758 50. Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by
759 elastography in NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:274-282.

760 51. Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, et al.
761 Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev
762 Gastroenterol Hepatol 2021;18:835-856.

763 52. Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD

and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-478.

765 53. Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A. MicroRNAs as controlled systems and
 766 controllers in non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:15079-15086.

Fang Z, Dou G, Wang L. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J
Biol Sci 2021;17:1851-1863.

769 55. Qian X, Zong W, Ma L, Yang Z, Chen W, Yan J, Xu J. MM-associated circular RNA downregulates
770 microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells.
771 Bioengineered 2022;13:9294-9300.

56. Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S.
Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).
Microrna 2018;7:215-222.

775 57. Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, et al. Analysis of
776 association between circulating miR-122 and histopathological features of nonalcoholic fatty liver
777 disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 2016;16:141.

58. Wang W, Min L, Qiu X, Wu X, Liu C, Ma J, Zhang D, et al. Biological Function of Long Non-coding
RNA (LncRNA) Xist. Front Cell Dev Biol 2021;9:645647.

780 59. Atanasovska B, Rensen SS, Marsman G, Shiri-Sverdlov R, Withoff S, Kuipers F, Wijmenga C, et al.

781 Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis.
782 Cells 2021;10.

783 60. Chee D, Ng CH, Chan KE, Huang DQ, Teng M, Muthiah M. The Past, Present, and Future of
784 Noninvasive Test in Chronic Liver Diseases. Med Clin North Am 2023;107:397-421.

- 785 61. Bozaoglu K, Attard C, Kulkarni H, Cummings N, Diego VP, Carless MA, Shields KA, et al. Plasma
- 1 levels of soluble interleukin 1 receptor accessory protein are reduced in obesity. J Clin Endocrinol
 Metab 2014;99:3435-3443.
- 788 62. Gao R, Wang J, He X, Wang T, Zhou L, Ren Z, Yang J, et al. Comprehensive analysis of endoplasmic
- reticulum-related and secretome gene expression profiles in the progression of non-alcoholic fatty
 liver disease. Front Endocrinol (Lausanne) 2022;13:967016.
- 791 63. Reznik N, Fass D. Disulfide bond formation and redox regulation in the Golgi apparatus. FEBS Lett
 792 2022;596:2859-2872.
- 793 64. Ledesma D, Symes S, Richards S. Advancements within Modern Machine Learning Methodology:
- 794 Impacts and Prospects in Biomarker Discovery. Curr Med Chem 2021;28:6512-6531.
- 795 65. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, et al.
- 796 Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat
- 797 Biotechnol 2019;37:773-782.

799 Figure Legend

800

Figure 1. RNA sequencing data processing, integration, and analysis

- 802 A. Illustration of data processing.
- 803 B. Principal component analysis (PCA) based on the origin of datasets.
- 804 C. PCA based on normalized RNA abundance (nCount).
- 805 D. PCA based on NAS score.
- 806 E. PCA based on fibrosis scores.
- 807
- 808

Figure 2. Integrative transcriptome and proteomics analysis to identify NAFLD biomarkers

A. Heatmap presentation of 1021 up-regulated genes in cluster 4 associated with increasing NAS scores.

813 B. Heatmap presentation of 643 down-regulated genes in cluster 14 associated with 814 increasing NAS scores.

- C. Protein cluster of 148 up-regulated proteins associated with increasing NAFLDseverity in PXD011839.
- D. Protein cluster of 114 down-regulated proteins associated with increasing NAFLDseverity in PXD011839.

E. (UP) Venn diagram showing 16 overlapping genes between up-regulated genes identified by RNA-seq, up-regulated proteins in the plasma, and secreting proteins. (DOWN) Venn diagram showing 22 overlapping genes between down-regulated genes identified by RNA-seq, down-regulated proteins in the plasma, and secreting proteins.

824

Figure 3. Relationship between QSOX1/IL1RAP and NAS/fibrosis scores in integrative RNA-seq data of the human liver.

- A. Box plot of QSOX1 gene expressions grouped by NAS scores (N0, N1-4, N5-8).
- 828 B. Box plot of QSOX1 gene expressions grouped by fibrosis stages (F0, F1-2, F3-4).
- 829 C. Box plot of IL1RAP gene expressions grouped by NAS scores (N0, N1-4, N5-8).
- D. Box plot of IL1RAP gene expressions grouped by fibrosis stages (F0, F1-2, F3-4).
- E. Box plot of QSOX1/IL1RAP gene expression ratio grouped by NAS scores (N0, N1-4, N5-8).
- F. Box plot of QSOX1/ IL1RAP gene expression ratio grouped by fibrosis stages (F0,
 F1-2, F3-4).
- Statistical testing was performed using the Wilcoxon rank sum test, with p-valuesshown in the plot.
- 837

838 Figure 4. Comparison of plasma protein QSOX1/IL1RAP between healthy 839 individuals and NAFLD at various stages.

A-B. Box plots of plasma QSOX1 (A) and IL1RAP (B) protein levels in healthy
individuals, NAFLD patients, and cirrhosis patients quantified by mass spectrometry
in the NAFLD proteomics cohort.

- 843 C. Box plots of plasma QSOX1 and IL1RAP protein ratios in healthy controls, NAFLD
- patients, and cirrhosis patients quantified by mass spectrometry in the NAFLD proteomics cohort.
- 846 D-E. Box plots of plasma QSOX1 (D) and IL1RAP (E) protein levels in healthy controls
- and NAFLD groups (pg/ml) measured by ELISA.
- 848 F. Box plot of plasma QSOX1 and IL1RAP protein ratio.
- 849 Statistical testing was performed using the Wilcoxon rank sum test, with p-values 850 shown in the plot.
- 851

852 Figure 5. Quantification of liver QSOX1 and IL1RAP levels in NAFLD patients by IHC.

- A. Representative IHC images of QSOX1 and IL1RAP in liver biopsies from mild NAFLD
- patients (N0-4, F0-2) and severe NAFLD patients (N5-8, F3-4).
- 855 B. The integrated density of QSOX1 IHC. Box plots showing the log10 value.
- 856 C. The integrated density of IL1RAP IHC. Box plots showing the log10 value.
- D. Box plot of QSOX1 and IL1RAP ratio of the integrated density quantified with IHC.
- 858 Statistical testing was performed using t-test, with p-values shown in the plot.
- 859
- 860 Table 1

| Table 1: Characteristics of the populations studied | | | | | | | |
|--|-------------------|------------------|-----------------|----------------|--------------|-----------------|-----------------|
| A total of 625 human liver samples of the full histological range from normal, NAFL, NASH to cirrhosis with the NAS (N) and fibrosis (F) scores provided in the database or original articles. | | | | | | | |
| Sample distribution of | F0 | F1 | F2 | F3 | F4 | Age (yrs) | BMI (kg/m2) |
| NAS and FIB | | | | | | $mean \pm S.D.$ | mean \pm S.D. |
| N0 (n) | 81 | 1 | 1 | - | 1 | 46.4 ± 10.0 | 35.4 ± 9.1 |
| N1 (n) | 29 | 9 | 1 | - | 1 | 42.8 ± 12.7 | 36.1 ± 6.6 |
| N2 (n) | 27 | 10 | 1 | - | 1 | 51.9 ± 5.8 | 35.1 ± 6.0 |
| N3 (n) | 46 | 72 | 9 | 5 | 3 | 49.8 ± 9.4 | 34.6 ± 8.9 |
| N4 (n) | 30 | 19 | 20 | 15 | 3 | 49.6 ± 9.5 | 33.9 ± 4.6 |
| N5 (n) | 7 | 41 | 75 | 20 | 5 | 52.4 ± 11.7 | 32.5 ± 5.5 |
| N6 (n) | 1 | 18 | 17 | 18 | 3 | 53.2 ± 8.5 | 34.5 ± 5.6 |
| N7 (n) | - | 1 | 14 | 11 | 1 | 49.4 ± 9.8 | 36.3 ± 7.2 |
| N8 (n) | - | - | 2 | 4 | 2 | 54 ± 0.0 | 31.3± 0.0 |
| Age (yrs) mean ± S.D. | 46.6 ± 9.6 | 49.0 ± 10.6 | 53.2 ± 11.3 | 54.7 ± 6.0 | 54.8 ± 5.4 | | |
| $\frac{BMI(kg/m2)}{mean \pm S.D.}$ | 37.1±8.3 | 32.4 ± 5.6 | 33.1 ± 7.0 | 32.5 ± 2.9 | 32.6 ± 2.2 | | |
| Gender n(male/female) | 221(105/116) * | 171 (108/63)* | 140 (64/76)* | 73 (35/38)* | 20 (11/9)* | | |
| Table 1. *The ratio of gender was estimated according to the gender ratio in the original articles. BMI, body mass index: N. NAS score: F. Fibrosis score. | | | | | | | |

861

862

863

864

865



Created with BioRender.com

medRxiv preprint doi: https://doi.org/10.1101/2023.07.26.23293038; this version posted May 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.













A medRxiv preprint doi: https://doi.org/10.1101/2023.07.26.23293038; this version posted May 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

A medRxiv preprint doi: https://doi.org/10.1101/2023.07.26.23293038; this version posted May 1, 2024. The copyright holder for this preprint (which was not certified by performed) is the author/funder, who has granted medRxiv a license to clipplay the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Supplementary File

A gene-based clustering approach reveals QSOX1/IL1RAP as promising biomarkers for the severity of non-alcoholic fatty liver disease

Wenfeng Ma 1,2,3,4, Jinrong Huang 2, Benqiang Cai 1,4, Mumin Shao 6,7, Xuewen Yu 6,7, Mikkel Breinholt Kjær 5,8, Minling Lv 1,4, Xin Zhong 1,4, Shaomin Xu 1,4, Bolin Zhan 1,4, Qun Li 1,4, Qi Huang 1,4, Mengqing Ma 1,4, Lei Cheng 2, Yonglun Luo 2,3*, Henning Grønbæk 5*, Xiaozhou Zhou 1,4*, Lin Lin 2,3*

1 Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518033, China.

2 Department of Biomedicine, Aarhus University, Aarhus, Denmark.

3 Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.

4 Department of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, China.

5 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.

6 Department of Pathology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518033, China.

7 Department of Pathology, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, China.

8 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

* = corresponding author

This supplementary file contains: Supplementary Figure S1-S5

Supplementary Figure S1



Supplementary Figure S1. t-SNE visualization of gene clusters

Visualization of gene expression profiling clusters across NAFLD progression with the tdistributed stochastic neighbor embedding (t-SNE) statistical method. Each dot represents one protein coding gene (n = 17,946). A graph-based clustering approach was used. The dimensions of reduction were set to 1:20 and visualized with a resolution of 2.3.

Supplementary Figure S2



medRxiv preprint doi: https://doi.org/10.1101/2023.07.26.23293038; this version posted May 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Supplementary Figure S2 Heatmap presentation of gene expression profile along NAFLD

progression.

A. Heatmap presentation of 1021 up-regulated genes in cluster 4 associated with increasing fibrosis scores.

B. Heatmap presentation of 643 down-regulated genes in cluster 14 associated with increasing fibrosis scores.

C and D. Contrary to genes in cluster 4 and 14, C and D displayed gene clusters with chaotic gene expression patterns associated with both NAS scores and fibrosis scores.

Supplementary Figure S3



Supplementary Figure S3 Heatmap presentation of ECM gene expression profile

A. Scale gene expression profile of multiple genes involved in the ECM process according to NAS scores. B. Scale gene expression profile of multiple genes involved in the ECM process according to fibrosis scores. Genes were clustered based on profile similarity. Genes expression level was scaled for heatmap presentation (also see the NAFLD-DB).

Supplementary Figure S4



Supplementary Figure S4 Heatmap presentation of Cytochrome P450 superfamily gene expression profile

A. Scale gene expression profile of multiple genes involved in the Cytochrome P450 superfamily according to NAS scores. B. Scale gene expression profile of multiple genes involved in the Cytochrome P450 superfamily according to fibrosis scores. Genes were clustered based on profile similarity. Genes expression level was scaled for heatmap presentation (also see the NAFLD-DB).

Supplementary Figure S5



Supplementary Figure S5 Heatmap presentation of expression profile for 32 biomarker genes

A. Scale gene expression profile of 38 biomarker genes (16 up-regulation, 22 downregulation) according to NAS scores. B. Scale gene expression profile of 38 biomarker genes according to fibrosis scores. Genes were clustered based on profile similarity. Genes expression level was scaled for heatmap presentation (also see the NAFLD-DB). This figure is related to Figure 2E.

List of Supplementary Tables

Supplementary Table 1

The RNA-seq data of human liver samples.

Supplementary Table 2

GO enrichment results for genes in cluster 4 (up-regulation) and cluster 14 (down regulation).

Supplementary Table 3

List of secreting protein-encoding genes in cluster 4, and 14 of RNA-seq analysis. Representing PMID supporting that the candidate gene as potential biomarker for NAFLD was listed. Note: this is a noncomprehensive list.

Supplementary Table 4

Performance Characteristics of QSOX1, IL1RAP, and the QSOX1/IL1RAP ratio in proteomics data and the results of ELISA.

Supplementary Table 5

Metadata for NAFLD patients and control participants involved in the ELISA validation study.